KORU Medical Systems demonstrated significant revenue growth and international expansion, alongside advancements in product development and achieving positive cash flow. However, challenges such as a decline in gross margin and anticipated domestic inventory reductions present concerns.

Company Guidance -

Q3 2025

During the KORU Medical Systems Q2 2025 earnings call, the company reported a record revenue of $10.2 million, marking a 21% year-over-year growth. This was driven by a 15% increase in domestic core revenues to $7.1 million and a 34% growth internationally to $2.2 million. The Pharma Services and Clinical Trials segment also saw a significant 42% increase, reaching $900,000. Gross margins for the quarter were 63.5%, slightly down by 150 basis points due to tariff impacts and prior inventory adjustments. Cash usage was reduced to $600,000, with the company ending the quarter with an $8.1 million cash balance. KORU raised its full-year revenue guidance to $39.5-$40.5 million, anticipating 18%-20% growth, while reiterating gross margin expectations of 61%-63% and projecting positive cash flow from operations for the year.

Record Revenue Achievement

KORU Medical Systems reached a historic milestone in Q2 2025 with over $10 million in revenue, a growth of over 20%.

Strong International Expansion

International revenue grew by over 30%, driven by expansion into new geographies and successful prefilled syringe market conversion in Europe.

Pharma Services and Clinical Trials Growth

Pharma Services and Clinical Trials segment saw strong growth with revenues up 42%, driven by clinical trial orders from a non-Ig partner.

Advancement in Product Development

Launched Phase I flow controller ahead of schedule and next-gen pump development is on track, expected to be submitted for 510(k) by Q4 2025 to Q1 2026.

Cash Flow and Profitability

Achieved positive cash flow from operations for the first half of 2025, with expectations to maintain or improve cash balance in second half.

REPRO-MED Systems (KRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

KRMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.02 / -	-0.03	―	―	―
Aug 06, 2025	2025 (Q2)	-0.02 / 0.01	-0.01	200.00% (+0.02)
May 07, 2025	2025 (Q1)	-0.03 / 0.00	-0.04	―
Mar 12, 2025	2024 (Q4)	-0.03 / -0.03	-0.02	-50.00% (>-0.01)
Nov 13, 2024	2024 (Q3)	-0.04 / -0.03	-0.03	0.00% (0.00)
Aug 07, 2024	2024 (Q2)	-0.04 / -0.01	-0.05	80.00% (+0.04)
May 01, 2024	2024 (Q1)	-0.04 / -0.04	-0.05	20.00% (+0.01)
Mar 13, 2024	2023 (Q4)	-0.04 / -0.02	-0.04	50.00% (+0.02)
Nov 08, 2023	2023 (Q3)	-0.05 / -0.03	-0.03	0.00% (0.00)
Aug 09, 2023	2023 (Q2)	-0.06 / -0.05	-0.06	16.67% (<+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

KRMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$3.26	$3.87	+18.71%
May 07, 2025	$2.72	$3.29	+20.96%
Mar 12, 2025	$3.28	$2.70	-17.68%
Nov 13, 2024	$3.20	$3.08	-3.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does REPRO-MED Systems (KRMD) report earnings?

REPRO-MED Systems (KRMD) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is REPRO-MED Systems (KRMD) earnings time?

REPRO-MED Systems (KRMD) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is KRMD EPS forecast?

KRMD EPS forecast for the fiscal quarter 2025 (Q3) is -0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing